Clinical Trials
40 trialsNCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT05111353 2026-05-06
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
Phase 1 Completed
NCT06614140 2026-04-22
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
Phase 1/2 Completed
NCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03206047 2025-03-13
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT02834052 2024-06-07
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Augusta University
Phase 1/2 Completed
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT01188096 2023-06-12
Poly-ICLC
Wake Forest University Health Sciences
Phase 2 Completed
NCT03359239 2023-05-16
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02166905 2023-02-24
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT00616941 2022-10-12
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02334735 2022-09-15
A Comparison of Matured Dendritic Cells and MontanideĀ® in Study Subjects With High Risk of Melanoma Recurrence
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03262103 2022-09-10
Neoadjuvant HiltonolĀ® (PolyICLC) for Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01834248 2022-07-22
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT02873819 2022-03-08
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Phase 2 Completed
NCT02129075 2021-11-16
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02544880 2021-06-15
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
University of Miami
Phase 1 Completed
NCT03380871 2021-02-26
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
BioNTech SE
Phase 1 Completed
NCT02897765 2021-02-25
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech SE
Phase 1 Completed
NCT02721043 2021-01-11
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT01245673 2020-04-06
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
University of Pennsylvania
Phase 2 Completed
NCT00694551 2019-10-04
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00795457 2019-08-30
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT02947854 2019-08-28
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
PCI Biotech AS
Phase 1 Completed
NCT00262730 2019-06-12
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00058123 2018-08-21
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT00986609 2018-07-23
MUC1 Vaccine for Triple-negative Breast Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01241162 2017-05-09
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
University of Louisville
Phase 1 Completed
NCT01734564 2017-04-11
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Completed
NCT01410968 2016-12-09
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma
Medical University of South Carolina
Phase 1 Completed
NCT00948961 2016-06-27
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Phase 1/2 Completed
NCT01920191 2016-04-20
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
University Hospital, Geneva
Phase 1/2 Completed
NCT00874861 2015-12-08
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT01008527 2015-09-24
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed